Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Autore:
Przepiorka, D; van Besien, K; Khouri, I; Hagemeister, F; Samuels, B; Folloder, J; Ueno, NT; Molldrem, J; Mehra, R; Korbling, M; Giralt, S; Gajewski, J; Donato, M; Cleary, K; Claxton, D; Braunschweig, I; Andersson, B; Anderlini, P; Champlin, R;
Indirizzi:
Univ,Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston Univ Texas Houston TX USA 77030 Dept Blood & Marrow Transplantat, Houston Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 Ctr, Dept Lymphoma, Houston, TX 77030 USA UnivUSAxas, MD Anderson Canc Ctr, Dept Diagnost Imaging, Houston, TX 77030Univ Texas Houston TX USA 77030 Dept Diagnost Imaging, Houston, TX 77030 Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 c Ctr, Dept Pathol, Houston, TX 77030 USA
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 5, volume: 10, anno: 1999,
pagine: 527 - 532
SICI:
0923-7534(199905)10:5<527:CECAMA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; TOTAL-BODY IRRADIATION; LOW-GRADE LYMPHOMA; BEAM CHEMOTHERAPY; AUTOLOGOUS TRANSPLANTATION; LINE THERAPY; TOXICITY;
Keywords:
allogeneic transplantation; BEAM; lymphoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Przepiorka, D Baylor77030 Med, Ctr Cell & Gene Therapy, 6565 Fannin St,M964, Houston, TX Baylor Coll Med 6565 Fannin St,M964 Houston TX USA 77030 TX
Citazione:
D. Przepiorka et al., "Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma", ANN ONCOL, 10(5), 1999, pp. 527-532

Abstract

Background: The combination of carmustine, etoposide, cytarabine and melphalan (BEAM) is an effective autologous transplantation preparative regimen for lymphoma and has little toxicity, but the feasibility and tolerance of BEAM as a preparative regimen for allogeneic transplantation has not been established. Patients and methods: Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m(2) i.v. day -6, etoposide 200 mg/m(2) i.v. followed by cytarabine 200 mg/m(2) i.v. twice daily days -5 to -2, melphalan 140 mg/m(2) i.v. day -1, and marrow or blood stem cells from an HLA-identical donor on day 0. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease (GVHD). Results: Median time from transplantation was 20 mos (range 6-32 months). Median maximal regimen-related toxicity grade was 2, and four patients (13%) had a grade 3-4 regimen-related toxicity. Two patients had idiopathic interstitial pneumonitis. One patient had primary graft failure, and a second had autologous reconstitution documented at three months posttransplant. Grades 2-4 acute GVHD occurred in 31%, grades 3-4 in 16%, and chronic GVHD in54%. Day-100 survival was 70%. Twenty-three patients achieved a complete response. The two-year relapse rate was 23%, survival was 48%, and disease-free survival (DFS) was 42%. Conclusions: BEAM supports engraftment of allogeneic transplants and is a tolerable preparative regimen for allogeneic transplantation for lymphoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 18:27:38